Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
|Podcasts|December 19, 2018
Exploring Strides Made in Ovarian Cancer & STS in Stanford
Author(s)Onclive Team
We headed to Stanford, California, for a State of the Science Summit on Ovarian Cancer and Soft Tissue Sarcoma, which focused on recent advances made in the treatment landscapes.
Advertisement
On October 25th, we visited Stanford, California, for a State of the Science Summit on Ovarian Cancer and Soft Tissue Sarcoma. At the meeting, faculty from Stanford Medicine discussed advances made in the treatment landscapes, touching on available modalities, such as immunotherapy, antibody drug conjugates, and PARP inhibitors.
Advertisement
Related to this article
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
3
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
4
Researchers Uncover How Aggressive Breast Cancer May Spread to the Brain
5